Researchers at UT Southwestern Medical Heart led a research revealed in JAMA Community Open which discovered that particular chemotherapies are related to an elevated long-term...
The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
Throughout Breast Most cancers Consciousness Month, Dr. Komal Jhaveri, a breast medical oncologist and early drug growth specialist at Memorial Sloan Kettering...
Dr. Evan Garfein, chief of plastic and reconstructive surgical procedure at Montefiore, shares how 3D printing and tissue-engineered applied sciences could improve...
